论文部分内容阅读
目的探讨来曲唑与克氯米芬用于多囊卵巢综合征促排卵的临床疗效。方法选取我院2009年6月至2010年6月收治的多囊卵巢综合征患者86例,随机分为来曲唑组和克氯米芬组,每组43例。来曲唑组采用口服来曲唑进行促排卵,克氯米芬组采用口服克氯米芬进行促排卵,比较两组患者的排卵率、妊娠数、子宫内膜厚度以及早期流产数等指标。结果克氯米芬组排卵数39例(90.7%),来曲唑组34例(79.1%),克氯米芬组高于来曲唑组(P<0.05);来曲唑组妊娠率、内膜厚度显著优于克氯米芬组(P<0.05);来曲唑组的早期流产率也明显低于克氯米芬组(P<0.05)。结论来曲唑用于多囊卵巢综合症患者临床疗效优于克氯米芬,且无子宫内膜变薄、多胎妊娠、卵巢过度刺激综合征等并发症,具有临床推广价值。
Objective To investigate the clinical efficacy of letrozole and clomiphene citrate for ovulation induction in patients with polycystic ovary syndrome. Methods Totally 86 patients with polycystic ovary syndrome who were admitted to our hospital from June 2009 to June 2010 were randomly divided into letrozole group and clomiphene citrate group, with 43 cases in each group. Oral letrozole was used in the letrozole group to induce ovulation, and clomiphene citrate group was orally administered with clomiphene citrate. Ovulation rate, pregnancy rate, endometrial thickness and early abortion were compared between the two groups. Results The number of ovulation in the clomiphene citrate group was 39 (90.7%), that in the letrozole group (79.1%) and that in the clomiphene citrate group was higher than that in the letrozole group (P <0.05) Intimal thickness was significantly better than that of clomiphene citrate (P <0.05). The early abortion rate of letrozole group was also significantly lower than that of clomiphene citrate group (P <0.05). Conclusion Letrozole is superior to clomiphene in patients with polycystic ovary syndrome and has no complications such as endometrial thinning, multiple pregnancy and ovarian hyperstimulation syndrome, and has clinical value of popularization.